Trials / Terminated
TerminatedNCT05201794
A Study of JNJ-64281802 for the Prevention of Dengue Infection
A Phase 2, Randomized, Double-blind, Placebo-controlled, Double-dummy, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue Infection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,595 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to the last day of dosing among participants who have no evidence of current DENV infection at baseline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64281802 | JNJ-64281802 tablets will be administered orally as per the defined regimens. |
| DRUG | Placebo | Matching placebo for each dose level as tablet will be administered orally. |
Timeline
- Start date
- 2023-02-22
- Primary completion
- 2024-06-26
- Completion
- 2024-06-26
- First posted
- 2022-01-21
- Last updated
- 2025-07-31
- Results posted
- 2025-07-31
Locations
38 sites across 9 countries: Brazil, Colombia, Malaysia, Mexico, Panama, Peru, Philippines, Puerto Rico, Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05201794. Inclusion in this directory is not an endorsement.